Physician profile
James A Fox
NPI 1144224056
$12,226.31
in general payments reported to CMS, 2019-2025
49 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,416 · 2021: $1,943 · 2022: $1,782 · 2023: $1,548 · 2024: $1,537 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,975 · Honoraria: $350 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,975.33 |
| Honoraria | $350.00 |
| Education | $113.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,039.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,662.07 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,476.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,239.32 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $632.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $440.98 | 2019-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $427.84 | 2021-2024 | |
| Kaleo, INC. | $361.20 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $338.31 | 2019-2025 | Xolair |
| Amgen INC. | $334.98 | 2019-2025 | Otezla, Tezspire |
| Biocryst US Sales Co., LLC | $275.91 | 2021-2025 | Orladeyo |
| Shire North American Group INC | $268.33 | 2019 | |
| Covis Pharma Gmbh | $267.60 | 2021-2023 | |
| Pharming Healthcare, INC. | $221.16 | 2019-2025 | Ruconest |
| Mayne Pharma Commercial LLC | $185.96 | 2019-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.